Bovine herpesvirus type 5 (BoHV-5) is the agent of meningoencephalitis, an important disease of cattle in South America. The neuropathogenesis of BoHV-5 infection is poorly understood and most previous research focused on the role of envelope glicoproteins in neurovirulence. Thymidine kinase (TK) is a viral enzyme necessary for virus replication in neurons and, therefore, represents a potential target for virus attenuation. The selection and characterization of BoHV-5 variants resistant to the nucleoside analog brivudin (BVDU), which selects TK-defective viruses is here described. Several BVDU-resistant clones were obtained after multiple passages in tissue culture in the presence of BVDU and one clone (BoHV-5/R-27) was further characterized. The selected clone replicated to similar titers and produced plaques with similar size and morphology to those of wild-type virus (SV507/99). The genetic stability of the resistant virus was demonstrated after ten passages in cell culture in the absence of the drug. Moreover, the drugresistant virus showed reduced virulence in a rabbit model: virus inoculation in four rabbits did not result in disease, in contrast with 75% morbidity (3/4) and 50% mortality (2/2) among rabbits inoculated with the parental virus. These results demonstrate that BoHV-5 is sensitive to BVDU and that drug-resistant mutants can be readily selected upon BVDU treatment. BVDU-resistant mutants, likely defective in TK, retained their ability to replicate in tissue culture yet were attenuated for rabbits. This strategy to obtain TK-defective BoHV-5 may be useful to study the role of TK in BoHV-5 neuropathogenesis and for vaccine development.
INTRODUCTION
Bovine herpesvirus type 5 (BoHV-5) is the agent of necrotizing meningoencephalitis, but sporadically has been also isolated from cases of genital disease, abortions and systemic infection in calves (23) . Unlike bovine herpesvirus type 1 (BoHV-1), BoHV-5 seems to have a more limited geographic distribution and has been frequently isolated from outbreaks of neurological disease in South American countries such as Brazil, Argentina and Uruguay (22, 25, 30) . (9, 20) . The viral genome encodes around 70 different polypeptides, which include glycoproteins, structural, regulatory proteins and enzymes (9) . Like all known herpesviruses, BoHV-5 encodes its own thymidine kinase (TK), which based on the homology with human herpes simplex virus (HSV) and BoHV-1, is an enzyme involved in the metabolism of deoxyribonucleotides in non-replicating cells (9, 24, 26) . The role of TK in the herpesvirus replication is to supply a pool of deoxyribonucleotides for viral DNA synthesis in non dividing cells such as neurons (26, 31) . As TK is not required for virus replication in cell culture, its gene has been classified as non-essential. Nonetheless, TK activity is necessary for the full expression of virulence in vivo and its deletion from HSV-1, BoHV-1 and pseudorabies virus (PRV) genomes is associated with significant reduction in virulence (1, 3, 16, 27) . Therefore, TK deletion has become an attractive target for gene manipulation of herpesviruses aiming to obtain attenuated viruses for vaccine use (3, 10, 17, 26, 28) .
The ability to establish latent infection seems not to be affected in TK-negative viruses, but its reactivation and subsequent replication are seriously impaired (26) . The substrates for herpesvirus TK are deoxypyrimidine nucleosides and synthetic nucleoside analogs such as acyclovir (ACV), penciclovir (PCV), ganciclovir (GCV) and brivudin (BVDU) (18, 26, 31) . Since BoHV-5 displays a marked neurotropism and its replication in the brain results in severe neurological signs and neuropathology, it is reasonable to assume that TK plays an important role in BoHV-5 neuropathogenesis.
BoHV-5 neuropathogenesis is not completely understood, yet multiple factors -host, viral and environmental -probably influence the production of clinical signs and neuropathology (4, 19, 21, 25) . Most of the previous research to elucidate the pathogenesis of BoHV-5 focused on the role of envelope glicoproteins (5) (6) (7) 15) and very little has been done to determine the role of other viral products.
Different approaches have been developed to study the role of specific gene products on the biology of viruses.
Chemical induced selection or mutagenesis is a very well established mean to produce variants defective in certain gene products, especially TK and DNA polymerase (8, 12, 18) .
Brivudin (BVDU, E-5-bromovinyl-2'deoxyuridine) was first described in late 70's and it is commercially available in Europe to treat HSV-1 and varicella-zoster infections (8) .
Viruses expressing TKs resistant to BVDU activity have been selected and used to map TK active sites and to characterize its role in the biology of the virus in vivo and in vitro (1, 8, 18) .
In this study we describe the production and (9) . This virus is highly virulent for calves and rabbits (9, 22, 29) , and was used as the parental strain to produce/select the resistant viruses. The brivudin BVDU (E-5-bromovinyl-2'deoxyuridine) was a generous gift from Dr. Erik De Clercq (Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium).
The chemical was diluted in ultrapure sterile water at a concentration of 2.5mg/mL.
Cell citotoxicity assays
The toxicity of BVDU for CRIB cells was evaluated by using the Trypan Blue assay (2) . Briefly, different concentrations of BVDU were prepared in MEM with 0.5% fetal bovine serum and incubated in duplicate during 72 h in 6 well plates containing a preformed monolayer of CRIB cells.
Then, the cells were trypsinized and stained with 0.4% of Trypan Blue, counted in a Neubauer chamber and the cell viability was calculated.
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RESULTS
BVDU cell toxicity
The toxicity of BVDU for CRIB cells was evaluated by In a dose-response experiment, it was possible to observe that SV507/99 was sensitive to concentrations higher than 0.01µg/mL (Fig. 1B) . Concentrations of 0.1 and 1µg/mL reduced more than 50% of virus yield, and concentrations higher than 10µg/mL resulted in lack of detection of infectious virus in the cell supernatant. Infectious virus could not be detected in cell supernatants in which the cultures were maintained with concentrations higher of 100µg/mL, yet some positive staining for virus antigens using imunoperoxidase assay was observed (not shown). This indicates that virus replication was not totally inhibited, but reduced to very low levels.
Taken together, these results showed that BoHV-5 replication in tissue culture is sensitive, in a dose-dependent manner, to BVDU. Based on the known mechanism of drug action, these results also indicate that this inhibition is due to the impairment of viral TK activity.
Isolation and characterization of BoHV-5 BVDU-resistant mutants in vitro
Isolation of viral plaques that were able to grow after two rounds of treatment with BVDU was readily achieved. At least eighteen individual plaques were selected and picked after agar overlay assay, using the virus harvested from the second round of BVDU treatment. After plaque purification and amplification, the BVDU-resistant phenotype (R) was Results demonstrated that the efficiency and kinetics of replication were not significantly affected (Fig. 2) . Again, these results demonstrate that the acquisition of BVDU resistant phenotype by BoHV-5/R-27 was not associated with a reduced ability to replicate in tissue culture.
The genetic stability of the BoHV-5/R-27 resistant phenotype was evaluated after ten blind passages in cell culture in the absence of the drug. Viruses harvested at first and tenth passages were titrated and assayed, as described earlier, for the sensitivity to BVDU. Both passages of BoHV-5/R-27 (first and tenth) replicated to similar titers in the presence (1µg/mL) or absence of BVDU, indicating that alterations in TK leading to resistance were stable and did not revert to the wild type phenotype. 
Virulence in vivo
The virulence of BoHV-5/R-27 was tested in a rabbit model and compared to the parental virus. Inoculation of rabbits (n=4) with the parental strain was followed of 
DISCUSSION
We herein demonstrated that BoHV-5 is sensitive to BVDU, as previously described for other alphaherpesviruses should be able to replicate to high titers in tissue culture; must be attenuated, genetically stable and should induce a strong immune response, and would preferentially have a serological marker to discriminate between vaccinated and infected animals (26, 28) . In this case, the TK gene represents an attractive target for manipulation towards attenuation.
However, an additional deletion would be necessary to introduce a serological marker; and the envelope glycoproteins gE, gC, gI, or Us9 apparently represent adequate candidates for such (15, 16, 26, 28) .
In summary, we demonstrated that BoHV-5 is sensitive to BVDU and were able to produce BVDU-resistant mutants.
These mutants -likely defective in TK activity -retain their ability to grow in tissue culture, are genetically stable and showed a marked reduction in virulence in a rabbit model.
Although these mutants need further genetic characterization before use as vaccine candidates, the attenuated phenotype is a highly desirable trait towards vaccine development and may be also explored to study the role of TK in the pathogenesis of BoHV-5 neurological infection.
